Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTX 001

Next Previous
Drug Profile

LTX 001

Alternative Names: LTX-001

Latest Information Update: 26 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leal Therapeutics
  • Class Antidepressants; Antipsychotics; Mood stabilisers; Small molecules
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia
  • Clinical Phase Unknown Amyotrophic lateral sclerosis; Bipolar disorders; Major depressive disorder

Most Recent Events

  • 08 Aug 2026 Pharmacodynamics data from a preclinical study in Schizophrenia presented at the 179th Annual Meeting of the American Psychiatric Association (APA 2026)
  • 04 Aug 2026 Leal Therapeutics initiates enrolment in the phase I trial for Schizophrenia (Monotherapy) in USA (PO, Suspension) (NCT07734493)
  • 29 Jul 2026 Leal Therapeutics plans a phase I trial for Schizophrenia in the USA (PO) in August 2026 (NCT07734493)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top